Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

O Day

Showing results (171-180 of 501) with videos related to

Pageof 51
Sort By:
Drug Safety|October 23, 2020
Potential Safety Issues with Use of Sodium-Glucose Cotransporter 2 Inhibitors, Particularly in People with Type 2 Diabetes and Chronic Kidney DiseaseTamara Y Milder, Sophie L Stocker, Richard O Day, et al.
Chirality|January 1, 1992
The effect of the enantiomers of ibuprofen and flurbiprofen on the beta-oxidation of palmitate in the ratB Zhao, G Geisslinger, I Hall, et al.
Clinical Pharmacokinetics|April 5, 2000
Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitorN M Davies, A J McLachlan, R O Day, et al.
British Journal of Rheumatology|March 1, 1994
Bioavailability of hydroxychloroquine tablets in patients with rheumatoid arthritisA J McLachlan, S E Tett, D J Cutler, et al.
Chirality|January 1, 1994
Pharmacokinetics and pharmacodynamics of hydroxychloroquine enantiomers in patients with rheumatoid arthritis receiving multiple doses of racemateS E Tett, A J McLachlan, D J Cutler, et al.
Drugs|December 1, 1988
Variability in response to NSAIDs. Fact or fiction?R O Day, G G Graham, K M Williams, et al.
Metal-Based Drugs|January 1, 1994
Transcriptional regulation by gold(i) thiolates involving interaction with conserved cysteine residues in the photo-oncogene products jun and fosM L Handel, C K Watts, R O Day, et al.
Journal of Clinical Pharmacology|October 1, 1979
Pharmacokinetics of carprofen in plasma and synovial fluidJ E Ray, D N Wade, G G Graham, et al.
Clinical Pharmacokinetics|May 1, 1999
Pharmacokinetics of nonsteroidal anti-inflammatory drugs in synovial fluidR O Day, A J McLachlan, G G Graham, et al.
Australian and New Zealand Journal of Medicine|December 1, 1995
Hazards of low dose methotrexateP G Conaghan, D I Quinn, P M Brooks, et al.
Pageof 51

Showing results (171-180 of 501) with videos related to

Sort By:
Pageof 51
Drug Safety|October 23, 2020
Potential Safety Issues with Use of Sodium-Glucose Cotransporter 2 Inhibitors, Particularly in People with Type 2 Diabetes and Chronic Kidney DiseaseTamara Y Milder, Sophie L Stocker, Richard O Day, et al.
Chirality|January 1, 1992
The effect of the enantiomers of ibuprofen and flurbiprofen on the beta-oxidation of palmitate in the ratB Zhao, G Geisslinger, I Hall, et al.
Clinical Pharmacokinetics|April 5, 2000
Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitorN M Davies, A J McLachlan, R O Day, et al.
British Journal of Rheumatology|March 1, 1994
Bioavailability of hydroxychloroquine tablets in patients with rheumatoid arthritisA J McLachlan, S E Tett, D J Cutler, et al.
Chirality|January 1, 1994
Pharmacokinetics and pharmacodynamics of hydroxychloroquine enantiomers in patients with rheumatoid arthritis receiving multiple doses of racemateS E Tett, A J McLachlan, D J Cutler, et al.
Drugs|December 1, 1988
Variability in response to NSAIDs. Fact or fiction?R O Day, G G Graham, K M Williams, et al.
Metal-Based Drugs|January 1, 1994
Transcriptional regulation by gold(i) thiolates involving interaction with conserved cysteine residues in the photo-oncogene products jun and fosM L Handel, C K Watts, R O Day, et al.
Journal of Clinical Pharmacology|October 1, 1979
Pharmacokinetics of carprofen in plasma and synovial fluidJ E Ray, D N Wade, G G Graham, et al.
Clinical Pharmacokinetics|May 1, 1999
Pharmacokinetics of nonsteroidal anti-inflammatory drugs in synovial fluidR O Day, A J McLachlan, G G Graham, et al.
Australian and New Zealand Journal of Medicine|December 1, 1995
Hazards of low dose methotrexateP G Conaghan, D I Quinn, P M Brooks, et al.
Pageof 51